Modality
Multispecific
MOA
MALT1i
Target
CDK4/6
Pathway
Proteasome
ThymomaCRCSCD
Development Pipeline
Preclinical
~Sep 2020
→ ~Dec 2021
Phase 1
~Mar 2022
→ ~Jun 2023
Phase 2
Sep 2023
→ Feb 2030
Phase 2Current
NCT07503520
537 pts·Thymoma
2023-09→2030-02·Not yet recruiting
537 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-02-053.9y awayPh3 Readout· Thymoma
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P2/3
Not yet…
Catalysts
Ph3 Readout
2030-02-05 · 3.9y away
Thymoma
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07503520 | Phase 2/3 | Thymoma | Not yet recr... | 537 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C |